Evolus reported Q2 revenue of $84.08M with break-even earnings (EPS $-0.12), a critical inflection point for the toxin-focused company. The result reflects disciplined cost management and pricing power in the Jeuveau franchise, which has stabilized after aggressive discounting cycles. Analyst upgrades from Stifel and Wall Street Zen followed, with maintained buy ratings and $17 price targets.
The company raised 2026 guidance on the back of Q2 performance, signaling confidence in sustained profitability. For practice owners, Evolus' trajectory matters: as the company moves from cash-burn to cash-generation, its ability to fund rebate programs, loyalty initiatives, and market development spending becomes clearer. The break-even milestone also reduces refinancing risk and strengthens negotiating leverage with group purchasing organizations.